Ozempic Lawsuit | Criteria: Do I qualify for a Payout? Feb. 18, 2026

Ozempic lawsuit litigants who filed individually asserting a claim for stomach paralysis (Gastroparesis), bowel obstruction, GI issues and vision loss / NAION*** are paving the way for an onslaught of GLP-1 agonists weight loss drug lawsuits. These victims are seeking lucrative ozempic lawsuit settlement amounts. These GLP-1 lawsuits are widely known by the moniker of “ozempic lawsuit” although the lawsuits specifically include: Wegovy, Zepbound, Trulicity, Victoza, Rybelsus and Mounjaro lawsuits. Ozempic lawsuit settlement amounts that are predictions are set forth below.  There is no ozempic class action lawsuit in the United States. It is not clear why the general public looks at these GLP-1 weight loss lawsuits as a monolith, of sorts, under the moniker of “ozempic lawsuit.”  Strangly, some people who are taking mounjaro, for example, are searching google for a “lawsuit against ozempic.” These medications constitute a class of diabetes medication and weight loss prescriptions that are widely referenced as glucagon-like peptide-1 (GLP-1) receptor agonists. Industry insiders and the general public often describe these drugs as blockbuster diabetes and weight loss drugs. According to a nonpartisan health policy organization’s (KFF), plaintiffs in the lawsuits constitute a tiny fraction of the 12% of U.S. persons over 18 with a GLP-1 prescription. In 2025, nearly one in eight people, over 18, admitted that they had an active GLP-1 prescription pursuant to a report by the Kaiser Family Foundation.

Ozempic lawsuit

Legal analysts have estimated that the amount of liability for GLP-1 manufacturers could top $2 billion as a result of the scale and seriousness of the injuries alleged. Ozempic lawsuit settlement amounts will not likely be known for years while the pharmaceutical litigation plays out in courts across the United States. Ozempic and Mounjaro are FDA-approved diabetes drugs comprised of semaglutide, prescribed primarily for treatment of type 2 diabetes. Ozempic operates by stimulating insulin production (triggering insulin release) and lowering glucose production in the liver resulting in lower blood sugar levels. Wegovy and Zepbound are prescibed for weight loss. The medications mimic the body’s hormones to cause patients to feel fuller. In essence the medication slows down digestion. Below you will find an extensive Ozempic lawsuit update entitled: ‘ozempic lawsuit latest news.’

Ozempic Lawsuit Criteria

Do I qualify for a weight loss drug gastrointestinal adverse events side effects lawsuit a.k.a an ozempic lawsuit?

Weight Loss drug (Ozempic / Mounjaro lawsuit et al.) criteria to qualify for lawsuit | AS OF 02/15/2026:

1. Took a GLP-1 Drug (name brand drug / not compound version) manufactured by Novo Nordisk or Elli Lilly,

2. Must have one of the following diagnosis that required medical treatment or hospitalization (see below):

3. No weight loss / bariatric surgeries,

4. No radiation of the abdominal area within 12 months prior to onset of symptoms,

5. Need date initially prescribed,

6. Not a compound version.

1. Took a GLP-1 Drug (name brand drug / not compound version) manufactured by Novo Nordisk or Elli Lilly:

• Mounjaro (tirzepatide) Manufacturer: Elli Lilly and Company (type 2 diabetes)+++
• Ozempic, (semaglutide) Manufacturer: Novo Nordisk (type 2 diabetes)
• Rybelsus, (semaglutide tablets)  Manufacturer: Novo Nordisk
• Victoza, (liraglutide) Manufacturer: Novo Nordisk; Generic of Victoza^®(liraglutide injection 1.8mg), Teva Pharmaceuticals, Inc., 
• Saxenda, (liraglutide)  Manufacturer: Novo Nordisk (same as Victoza but for weight management)
• Trulicity, (dulaglutide) Manufacturer: Eli Lilly and Company
• Wegovy, (semaglutide) Manufacturer: Novo Nordisk (same active ingredients as Ozempic) (weight management)
• Zepbound (tirzepatide) Manufacturer: Elli Lilly and Company (identical active ingredient as Mounjaro) (weight management)

2. Must have one of the following diagnosis that required medical treatment or hospitalization:

1. Intraoperative pulmonary aspiration
2. Necrotizing pancreatitis (NP)
3. Ileus or bowel obstruction, with or without surgical treatment.
4. Pancreatic cancer (No prior history of cancer)
5. Esophageal injury requiring surgery.
6. Gallbladder removal (Prior to 03/2022) (Must have taken GLP-1 drug prior to the Gallbladder removal.) Wont accept in 2 year statute of limitations state unless there is a discovery rule that applies.
7. Severe or permanent stomach paralysis, Ozempic stomach paralysis.
8. Gastroparesis- diagnosed and treated. (May require gastric emptying study per Marston’s ruling although firms may accept claims without study with hospitalization)
9. Persistent vomiting which requires hospitalization and/or seen in the emergency room (ER) for IV fluids.
10. Gastrointestinal GI injury requiring surgery.
11. Deep vein thrombosis (DVT) and related injuries, including death. (Only well-controlled diabetics)
12. Non-arteritic anterior ischemic optic neuropathy (NAION) (sudden deprivation of blood flow into the optic nerve. May cause permanent vision loss)
13. Eye Injuries: such as vision changes, sudden blindness, optic nerve stroke, retinal stroke, visual acuity loss, color blindness, ischemia to optic nerve. (see below)
14. Severe and ongoing symptoms of nausea, vomiting, diarrhea, constipation or other gastrointestinal issues that are treated with emergency room visits, hospitalizations, multiple physician visits.
15. Neuropathy with Gastroparesis (GP***) If neuropathy diagnosis predates gastroparesis diagnosis, these potential lawsuits will be reviewed on a case by case basis!

3. No weight loss / bariatric surgeries,

4. No radiation of the abdominal area within 12 months prior to onset of symptoms,

5. Need date initially prescribed,

6. Not a compound version 

**** Means the co-occurrence of neuropathy (nerve damage) and gastroparesis (GP). This specific combination is a crucial focal point of the ozempic lawsuits in state and federal courts.

Criteria to qualify for a GLP-1 vision injury / loss lawsuit:

(Who qualifies for an ozempic vision loss lawsuit?)

• Vision Changes (sudden or severe after taking GLP-1RA medication. Must have a diagnosis.) 
• Sudden blindness 
• Optic nerve stroke
• Retinal stroke
• Visual acuity loss
  • Reduced sharpness or clarity of vision leading to difficulty seeing detailed objects or distances clearly.
• Color blindness
  • Eye Injury occurred within a time span of about a month.
• Severe or Sudden onset worsening of vision
• Eye Injury occurred within a time span of about a month (30 days+-)
• lschemia to optic nerve
• Wet macular degeneration

For vision injury or ozempic vision loss lawsuits, we are not accepting primary diagnosis of floaters, diabetic retinopathy, cataracts or glaucoma. (Unless the client experiences sudden blindness in one eye or it’s a NAION lawsuit)

++++ Eli Lilly’s tirzepatide products (Zepbound and Mounjaro) unite GLP-1 medication with a hormone that is hunger-related, named GIP. As a result, tirzepatide prescriptions lead to higher weight loss totals, on average, more than semaglutide. Mounjaro (tirzepatide) operates by mimicking a couple of natural hormones, GLP-1 and GIP. (glucose-dependent insulinotropic polypeptide) The combination provides a “twincretin” to improve appreciably blood sugar control. This leads to weight loss by increasing insulin, lowering appetite, and decelerating digestion. This makes it a dual agonist for important incretin hormones. GIP which is let go from the intestine, informs the pancreas organ to engage in secretion of insulin. This is important for the incretin effect which works with GLP-1 to reduce blood sugar and assist with losing weight.

Is ozempic being sued?

The Ozempic lawsuits that have been filed are premised on the theory that Novo Nordisk and the other manufacturers failed to properly warn victims of the dangers of Ozempic and other GLP-1 medications. Victims in the lawsuits assert that the manufacturers failed to properly warn of gastrointestinal risks and vison loss side effects among other allegations. Nearly identical assertions are also being pursued against other GLP-1 receptor agonists, such as Wegovy, Mounjaro, Rybelsus, Saxenda, and Trulicity. Victims continually report enduring digestive problems and gastrointestinal adverse events.  A “Failure to warn” theory of the case is a well-established legal doctrine in product liability law.

Ozempic works by stimulating insulin production and reducing glucose production in the liver helping to lower blood sugar levels. Recently, these drugs and their weight loss drug counterparts (Wegovy, Zepbound et al.) are extremely popular as an appetite suppressant and medication weight loss drug. Millions of people across the U.S.A and the world are prescribed Ozempic, Mounjaro and their counterparts for both weight loss and for treatment of type 2 diabetes. GLP-1 weight loss and diabetes medication are so widespread that 12% of adults in the U.S. report that they have been prescribed a GLP-1 drug at some point in the lives.

Manufacturers have disputed the legal allegations concerning gastroparesis and optic neuropathy

These prescriptions have become wildly popular as a weight loss medication in the recent past. The manufacturers have disputed the legal allegations concerning gastroparesis and optic neuropathy, asserting in court motions that the chance of a gastroparesis diagnosis is well-known by the public and that the manufacturers are not able to alter the medications’ design without the go ahead from the U.S. Food and Drug Administration (FDA).

Ozempic lawsuits on the rise

Ozempic lawsuit settlement amounts will not be known potentially for years. As of January 19th, 2026, over 3,000 lawsuits have been filed against Novo Nordisk and Eli Lilly in the Federal MDL alleging severe and often debilitating complications associated with the medications. (Update 02/08/26-Some of these lawsuits will now have to be dismissed because victims who suffered through Gastroparesis may now be required to get a gastric emptying study and cannot rely on clinical observations alone.)  Hundreds and perhaps thousands of potential Ozempic lawsuits for stomach paralysis were being held on the sidelines by various attorneys waiting for that evidentiary ruling from the MDL judge.  Many of these lawyers and victims suffering through gastroparesis are now scrambling to get gastric emptying studies so they can stake a claim to a potential Ozempic payout. 

Is there a lawsuit against ozempic seeking an Ozempic Payout?

Lawsuits against ozempic

The popularity of diabetes drug Ozempic and its counterpart Wegovy both manufactured by Novo Nordisk has soared due to the perceived effectiveness of the drugs as appetite suppressants. Ozempic usage has been fueled by celebrity endorsements as well as social-media promotion that has emphasized the weight loss advantages of the medications. Both drugs are made up of the drug, Semaglutide. Danish drugmaker Novo Nordisk outlined over $25 billion in world wide sales in 2024 off their popular semaglutide GLP-1 obesity medication. While Ozempic has gained acclaim as an off-label weight loss aid, prolonged use could expose individuals to health risks and Ozempic side effects, including Ozempic stomach paralysis, vision loss, pancreatitis, gallbladder disease (gallstones) and intestinal blockages (bowel obstruction).  Medical providers have bantied around an educated rough estimate that 10% of patients taking ozempic stop usage as a result of the severity of Ozempic side effects. Additionally, the introduction of Wegovy, an FDA-approved higher-dose version of Ozempic, intended to treat obesity, raises concerns about potential adverse effects. Victims are increasingly claiming that Ozempic jabs lead to gastroparesis.

What type of compensation may victims receive in an Ozempic settlement amount?

How much is the Ozempic lawsuit going to payout? The victims are demanding a settlement and compensation for:

• Payments for past and future medical bills caused by GLP-1 injuries
• Lost wages resulting from complications / side effects
• Compensation for lost earning capacity as a result of ozempic side effects
• Damages by way of settlement for pain and suffering, emotional distress & diminished loss of enjoyment of life
• Certain victims are demanding punitive damages against Novo Nordisk, Eli Lilly and others drug manufacturers.

Many victims are asking:

• Who is eligible for the Ozempic lawsuit?
• Who qualifies for the Wegovy lawsuit?
• Do I Meet The Ozempic Lawsuit Criteria?
• Is there a lawsuit against ozempic?

“Pulmonary aspiration is the passive process of oropharyngeal or gastric contents entering the trachea. During sedation, the pharyngeal function is impaired, and the peak pressure in the upper esophageal sphincter is decreased. This will cause a force reduction to propel content during swallowing and may lead to content penetrating the trachea.” Sciencedirect

Victims who endured gastroparesis after being prescribed Ozempic

Victims who endured gastroparesis after being prescribed Ozempic may be eligible to obtain compensation as a result of their suffering by pursuing an Ozempic lawsuit.  Ozempic lawsuit settlement amounts for gastroparesis are only speculation at this point in time. Currently there are pending lawsuits pertaining to Ozempic, Wegovy & Mounjaro, et al. These claims (as of July 2024) constitute an MDL, commonly referred to as an Ozempic class action lawsuit. The Ozempic MDL class action lawsuit pertains to Ozempic, Rybelsus, Mounjaro, Wegovy, and Trulicity.

How does ozempic work?

• Ozempic Slows Digestion: Ozempic mimics a (GLP-1) hormone that decelerates the speed that food exits the stomach (known as gastric emptying).
• More Fullness: This slowing feeling makes a person feel fuller for a longer period, reducing a persons appetite and lowering the amount of food intake.
• Enhanced Blood Sugar: Ozempic also informs the pancreas to deliver increased insulin when blood sugar is elevated and less glucagon, enhancing glucose control. 

Currently 13 states fully provide coverage for the medication under Medicaid. The Trump administration is looking to widen insurance coverage to more citizens. In 2026 there are oral weight-loss pills about to be approved by the FDA.

Weight loss drug lawsuit

Researchers compared Wegovy and Ozempic with competing weight-loss drugs,  which are all GLP-1 agonists and determined that:

• • • Patients had a nine times greater likelihood of a pancreatitis diagnosis. Pancreatitis is an inflammation of the pancreas.
    • Patients had a nine times greater likelihood of bowel obstruction. Bowel obstruction occurs when there is a blockage which stops food from going through either the small or large intestine. The United States Food and Drug Administration revised the ozempic label to add a complication called ileus. Ileus is a bowel blockage, which patients have reported as a complication of Ozempic.
    • Patients had a nine times greater likelihood of a gastroparesis diagnosis. Gastroparesis is otherwise known as stomach paralysis.

Ozempic bowel injury

These determinations were reached by researchers examining health insurance claims for more than 5,000 victims with an obesity diagnosis. These patients in the study did not have diabetes. All of the studied patients took GLP-1 agonists.  The GLP-1 agonists taken by these patients specifically includes Semaglutide.  Semaglutide is the active ingredient in Wegovy and Ozempic. Some of these patients were prescribed with an alternate weight-loss prescription such as bupropion-naltrexone. All patient prescriptions occurred between 2007 and 2020.

Ozempic Lawsuit claims and allegations

Is there an Ozempic class action lawsuit?

No. There is no Ozempic class action lawsuit. Even though there is no GLP-1 class action lawsuit, the logical question is: “is ozempic being sued?” An Ozempic Class Action lawsuit would be very unfortunate for victims.  On February 2nd, 2024 an Ozempic lawsuit commenced in the Eastern District of Pennsylvania federal court. This is a Multi District Litigation. The Ozempic MDL is known as MDL 3094 IN RE GLUCAGON-LIKE PEPTIDE- RECEPTOR AGONISTS (GLP-1RAS) PRODUCTS LIABILITY LITIGATION. An MDL is a collection of individual lawsuits with individual attorneys that are consolidated / centralized for motions, settlement and discovery etc.

Likelihood of severe complication from Ozempic:

• • • 9 times greater chance of pancreatitis diagnosis. Pancreatitis is an inflamed pancreas.
    • Greater than four times likelihood of suffering through bowel obstruction. Bowel obstruction is when a bowel blockage stops food from going through either of the intestines (small intestine of large intestine). In late 2023, the U.S. Food and Drug Administration modified the ozempic label to add ileus. Ileus is a bowel blockage. Bowel blockage can be an adverse side effect.
    • Greater than three times likelihood of a gastroparesis diagnosis. Gastroparesis is also is infamously known as stomach paralysis.

The basics:

• • • Ozempic and Wegovy both are comprised of the active component, semaglutide. This is similar to the hormone GLP-1 (glucagon-like peptide-1). GLP-1’s cause transfer of food to slow in the digestive system. This send a message that the stomach is full.
    • Mounjaro and Zepbound, have a different active ingredient, tirzepatide. Tirzeptide also has a hunger surpressing effect.
    • Wegovy and Zepbound are the only drugs greenlighted by the FDA for only weight loss. Moungaro (Eli Lilly) and Ozempic (Novo Nodisk) are only intended to be prescribed for treatment of type 2 diabetes. (Although, they are often prescribed off label for weight loss and Sleep Apnea)

Unveiling Manufacturer Responsibilities

The manufacturer, Novo Nordisk, falls short in addressing certain grave side effects linked to Ozempic and Wegovy. Stomach paralysis (gastroparesis), intestinal blockages, and even pancreatic cancer, potential and fatal gastric complications, are notably absent from their warnings.  The lack of warnings is leading to lawsuits against ozempic. Consequently, patients may remain unaware of the risks associated with these severe conditions, which might necessitate hospitalization and surgical intervention.

Investigating Claims- Not an ozempic class action lawsuit

Our team of medical drug attorneys is diligently investigating claims regarding these medications. If you have experienced health issues after using Ozempic, Wegovy, or other GLP-1 Receptor drugs for diabetes or weight loss, we urge you to reach out and explore your legal options.

Contact us: If you or a loved one has encountered pancreatic cancer, NAION, sudden vision loss, intestinal blockages, or stomach paralysis (gastroparesis) as a result of consuming Ozempic, Wegovy, or another GLP-1 Receptor drug, you could have grounds for a claim. Complete our form online or call TELEPHONE to connect with attorney David Slepkow for detailed information or to discuss a potential claim.

How much will the Ozempic settlement payout amounts be per victim?

Our guestimate is that victims with severe injuries such as Gastroparesis caused by Ozempic will receive an Ozempic payout between $350,000 to over 1 million in the case of a death. Ozempic lawsuit settlement amounts will vary based on the severity of the injury. Ozempic settlement payouts amounts can only be guessed because there have been no reported settlements.

Ozempic gallbladder lawsuit

Can Ozempic usage cause gallbladder disease? There have been Studies which indicate causation of Ozempic and a greater risk of gallbladder disease or gallstones. Currently, Elli Lilly warns users of gallbladder disease as a potential complication caused by Ozempic.

The risk of pulmonary aspiration during surgery

There is no meaningful evidence that Ozempic causes a major impact to the lungs. However, ozempic may be perilous when a surgery is required. In 2024, the FDA revised Ozempic’s warning label to alert the public to the risk of pulmonary aspiration in people who endured surgical procedures or surgeries which required deep sedation or anesthesia. Pulmonary aspiration is widely known by medical providers as a terrifying complication of sedation. Pulmonary aspiration happens when a victim inhales a portion of the contents of their stomach during a surgery. Pulmonary aspiration can result in death, which is the reason people are usually mandated to fast prior to surgery. Because, GLP-1s slow down the emptying of food process from the stomach, the customary fasting time period prior to a surgery may not be sufficient to circumvent the chance of pulmonary aspiration. The FDA seems circumspect, reasoning that the FDA has insufficient evidence to proffer any guidance on methods to decrease this risk.

The Evolution of Ozempic and Its Off-Label Use

Initially designed and approved in 2017 for Type 2 diabetes treatment, Ozempic’s unintended side effect of appetite suppression and consequential weight loss was promptly observed by clinicians. Subsequently, Novo Nordisk introduced Wegovy, a higher-dose iteration of Ozempic, gaining FDA approval in June 2021 to address weight gain and obesity in specific patients. Both medications have surged in popularity, leading to nationwide shortages. In 2022, their combined sales reached nearly $10 billion, with prescriptions continuing to surge.

Understanding the Active Ingredient

Semaglutide, the active ingredient in both Wegovy and Ozempic, falls under the category of GLP-1 (glucagon-like peptide-1). This compound emulates the GLP-1 satiety hormone within our bodies, allowing the medication to target brain regions that regulate appetite and food intake. To mitigate gastrointestinal side effects, the FDA recommends a gradual weekly increase in dosage. However, patients are often required to remain on Wegovy long-term, potentially for life, as discontinuing the drug can lead to rapid weight regain. Unfortunately, prolonged usage amplifies the risk of encountering adverse effects.

Uncovering Potential Health Risks

In 2023, the FDA’s disclosure of concerns conveyed through the FDA Adverse Event Reporting System (FAERS) signals potential safety risks associated with these medications. Among these risks, the threat of intestinal blockage emerges as a significant concern, carrying both serious and life-threatening implications.

Wegovy lawsuit

Furthermore, medical professionals have recently reported cases of stomach paralysis, scientifically known as gastroparesis. This condition disrupts the proper functioning of the stomach’s nerves and muscles, leading to prolonged retention of food within the stomach. Gastroparesis is often accompanied by symptoms such as:

• • • Indigestion
    • Nausea
    • Vomiting
    • Malnutrition
    • Abdominal bloating
    • Rapid satiety
    • Upper abdominal pain
    • Loss of appetite
    • Constipation

Our Expertise in Medical Drug Litigation

With vast experience in representing patients adversely affected by hazardous prescription and over-the-counter drugs, our legal team recognizes the limitations patients and their families may have in comprehending the complexities of their medications. If you suspect that a medication has caused harm or injury, our attorneys possess the resources and expertise to conduct thorough investigations and:

• • • Identify potentially harmful medications
    • Determine whether a medication led to harm
    • Evaluate the manufacturer’s adherence to FDA regulations
    • Ascertain the adequacy of warnings regarding potential side effects
    • Examine any wrongful or unlawful actions taken by the manufacturer concerning the medication
    • Identify any additional factors that could impact your potential claim

Ozempic (semaglutide) is a medication used to treat type 2 diabetes

Ozempic (semaglutide) is a medication used to treat type 2 diabetes. Like any medication, it can have side effects. It’s important to note that not everyone will experience these side effects, and some individuals may experience different side effects to varying degrees of severity. If you are prescribed Ozempic and are concerned about its side effects, it’s crucial to discuss them with your healthcare provider. Below are some common side effects associated with Ozempic:

• • 1. Gastrointestinal Issues:
       • Nausea
       • Vomiting
       • Diarrhea
       • Constipation
       • Abdominal pain or discomfort
    2. Injection Site Reactions:
       • Pain or redness at the injection site
       • Itching or rash
    3. Hypoglycemia (Low Blood Sugar):
       • This can occur if Ozempic is used in combination with other medications that lower blood sugar, like insulin or sulfonylureas.
       • Symptoms may include sweating, shakiness, dizziness, rapid heartbeat, confusion, and weakness.
    4. Allergic Reactions:
       • Although rare, allergic reactions can occur. Signs of an allergic reaction may include hives, itching, swelling (especially of the face, lips, tongue, or throat), severe dizziness, or difficulty breathing.
    5. Pancreatitis:
       • Some individuals may experience pancreatitis, which is inflammation of the pancreas. Symptoms may include severe abdominal pain, often radiating to the back, nausea, and vomiting.
    6. Gallbladder Problems:
       • Ozempic may increase the risk of gallbladder problems, such as gallstones.
    7. Thyroid Tumors:
       • In animal studies, Ozempic has been associated with an increased risk of thyroid tumors. However, this risk in humans is not well established.

Ozempic lawsuit

It’s important to follow your healthcare provider’s instructions carefully when taking Ozempic and to report any side effects promptly. If you experience severe or persistent side effects, or if you have concerns about your medication, contact your healthcare provider. They can adjust your treatment plan or recommend alternative medications if necessary. Additionally, it’s worth noting that Ozempic is typically just one part of a comprehensive treatment plan for type 2 diabetes, which may also include dietary and lifestyle changes. Always discuss your diabetes management plan with your healthcare team to ensure it meets your specific needs and goals.

Professor Andy Schmelz speaks out about Thyroid cancer

Andy Schmelz is an associate professor of pharmacy practice at Butler University. Professor Schmelz reiterated that gastrointestinal complications are commonplace among patients with a glp-1 scripts. Schmelz said, “Most patients will experience some kind of stomach-related side effect like nausea, vomiting, diarrhea, constipation… That’s fairly typical for medications that work like this.” Andy Schmelz points out that GLP-1 medications are mandated to have a black box black box warning for the dangers of thyroid tumors. Schmelz opined that: “The drugs have been found to increase the risk of thyroid tumors in mice.”  Schmelz went a step further when he stated, “Because of that, we definitely recommend patients use caution who have a family history or a personal history of thyroid cancer.”

GLP-1 scams

Consumers across the United States and especially in Wisconsin are reporting losing money to scams that promote discounted GLP-1 drugs. The Better Business Bureau reports upwards of 100 citizens targeted by internet retailers claiming to sell discounted GLP-1 medications. Some people have lost hundreds of dollars. Scammers are trying to capitalize on the skyrocketing demand for these medications. Some scams pimp  products such as Lipomax, Ozemburn and Prozenith. There have been reports of fake photos and fake videos  purporting to be physicians or celebrities such as Oprah Winfrey advocating GLP-1 arm patches as well as the “pink salt trick diet.”